NHS Logo
Image from Google Jackets

Are previous treatment interruptions associated with higher viral rebound rates in patients with viral suppression?

By: Contributor(s): Publication details: 2008ISSN:
  • 02699370
Uniform titles:
  • AIDS
Online resources: Summary: <div style="line-height: 17.999801635742188px;"><h4 style="margin: 0px 0.25em 0px 0px; text-transform: uppercase; float: left;"><span style="font-size: 10pt;">OBJECTIVE:</span></h4><p style="margin: 0px 0px 0.5em;"><span style="font-size: 8pt;"><span style="font-size: 10pt;">We investigated whether&nbsp;<span class="highlight">previous</span>&nbsp;<span class="highlight">treatment</span>&nbsp;<span class="highlight">interruptions</span>&nbsp;are&nbsp;<span class="highlight">associated</span>&nbsp;with a raised risk of&nbsp;<span class="highlight">viral</span>&nbsp;<span class="highlight">rebound</span>&nbsp;in individuals who have attained virological suppression.</span></span></p><h4 style="margin: 0px 0.25em 0px 0px; text-transform: uppercase; float: left;"><span style="font-size: 10pt;">METHODS:</span></h4><p style="margin: 0px 0px 0.5em;"><span style="font-size: 10pt;">All&nbsp;<span class="highlight">patients</span>&nbsp;achieving an undetectable&nbsp;<span class="highlight">viral</span>&nbsp;load while on&nbsp;<span class="highlight">therapy</span>&nbsp;were followed until&nbsp;<span class="highlight">viral</span>&nbsp;<span class="highlight">rebound</span>&nbsp;or the time of the last&nbsp;<span class="highlight">viral</span>&nbsp;load. Poisson regression was used to describe the independent impact of&nbsp;<span class="highlight">treatment</span>&nbsp;<span class="highlight">interruptions</span>&nbsp;on&nbsp;<span class="highlight">rebound</span>&nbsp;<span class="highlight">rates</span>.</span></p><h4 style="margin: 0px 0.25em 0px 0px; text-transform: uppercase; float: left;"><span style="font-size: 10pt;">RESULTS:</span></h4><p style="margin: 0px 0px 0.5em;"><span style="font-size: 10pt;">A total of 12,977&nbsp;<span class="highlight">patients</span>&nbsp;from the United Kingdom Collaborative HIV Cohort (UK CHIC) Study achieved a&nbsp;<span class="highlight">viral</span>&nbsp;load of less than 50 copies/ml. These&nbsp;<span class="highlight">patients</span>&nbsp;contributed a total of 37,314 person-years of follow-up. The overall&nbsp;<span class="highlight">rebound</span>&nbsp;rate was 8.07 (7.78, 8.36) per 100 person-years. In adjusted analyses,&nbsp;<span class="highlight">rates</span>&nbsp;of&nbsp;<span class="highlight">viral</span>&nbsp;<span class="highlight">rebound</span>&nbsp;were up to 64%&nbsp;<span class="highlight">higher</span>&nbsp;(rate ratio 1.64; 1.43, 1.88) in those who had previously interrupted&nbsp;<span class="highlight">therapy</span>&nbsp;compared with those who had not.&nbsp;<span class="highlight">Patients</span>&nbsp;who had interrupted at detectable&nbsp;<span class="highlight">viral</span>&nbsp;loads had up to a 74% (1.74; 1.42, 2.14)&nbsp;<span class="highlight">higher</span>&nbsp;chance of rebounding compared with those who had not interrupted with a detectable&nbsp;<span class="highlight">viral</span>&nbsp;load. We found no evidence to suggest interrupting&nbsp;<span class="highlight">treatment</span>&nbsp;at an undetectable&nbsp;<span class="highlight">viral</span>&nbsp;load was&nbsp;<span class="highlight">associated</span>&nbsp;with&nbsp;<span class="highlight">viral</span>&nbsp;<span class="highlight">rebound</span>.</span></p><h4 style="margin: 0px 0.25em 0px 0px; text-transform: uppercase; float: left;"><span style="font-size: 10pt;">CONCLUSION:</span></h4><p style="margin: 0px 0px 0.5em;"><span style="font-size: 8pt;"><span style="font-size: 10pt;">Among&nbsp;<span class="highlight">patients</span>&nbsp;with an undetectable&nbsp;<span class="highlight">viral</span>&nbsp;load, having previously interrupted&nbsp;<span class="highlight">therapy</span>&nbsp;while the&nbsp;<span class="highlight">viral</span>&nbsp;load was detectable is&nbsp;<span class="highlight">associated</span>&nbsp;with a raised risk of&nbsp;<span class="highlight">rebound</span>.</span></span></p></div>
Star ratings
    Average rating: 0.0 (0 votes)
Holdings
Item type Home library Collection Class number Status Date due Barcode
UNKNOWN Ferriman information and Library Service (North Middlesex) Online Staff publications for NMDX Available

NMUH Staff Publications

22

&lt;div style="line-height: 17.999801635742188px;"&gt;&lt;h4 style="margin: 0px 0.25em 0px 0px; text-transform: uppercase; float: left;"&gt;&lt;span style="font-size: 10pt;"&gt;OBJECTIVE:&lt;/span&gt;&lt;/h4&gt;&lt;p style="margin: 0px 0px 0.5em;"&gt;&lt;span style="font-size: 8pt;"&gt;&lt;span style="font-size: 10pt;"&gt;We investigated whether&amp;nbsp;&lt;span class="highlight"&gt;previous&lt;/span&gt;&amp;nbsp;&lt;span class="highlight"&gt;treatment&lt;/span&gt;&amp;nbsp;&lt;span class="highlight"&gt;interruptions&lt;/span&gt;&amp;nbsp;are&amp;nbsp;&lt;span class="highlight"&gt;associated&lt;/span&gt;&amp;nbsp;with a raised risk of&amp;nbsp;&lt;span class="highlight"&gt;viral&lt;/span&gt;&amp;nbsp;&lt;span class="highlight"&gt;rebound&lt;/span&gt;&amp;nbsp;in individuals who have attained virological suppression.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;h4 style="margin: 0px 0.25em 0px 0px; text-transform: uppercase; float: left;"&gt;&lt;span style="font-size: 10pt;"&gt;METHODS:&lt;/span&gt;&lt;/h4&gt;&lt;p style="margin: 0px 0px 0.5em;"&gt;&lt;span style="font-size: 10pt;"&gt;All&amp;nbsp;&lt;span class="highlight"&gt;patients&lt;/span&gt;&amp;nbsp;achieving an undetectable&amp;nbsp;&lt;span class="highlight"&gt;viral&lt;/span&gt;&amp;nbsp;load while on&amp;nbsp;&lt;span class="highlight"&gt;therapy&lt;/span&gt;&amp;nbsp;were followed until&amp;nbsp;&lt;span class="highlight"&gt;viral&lt;/span&gt;&amp;nbsp;&lt;span class="highlight"&gt;rebound&lt;/span&gt;&amp;nbsp;or the time of the last&amp;nbsp;&lt;span class="highlight"&gt;viral&lt;/span&gt;&amp;nbsp;load. Poisson regression was used to describe the independent impact of&amp;nbsp;&lt;span class="highlight"&gt;treatment&lt;/span&gt;&amp;nbsp;&lt;span class="highlight"&gt;interruptions&lt;/span&gt;&amp;nbsp;on&amp;nbsp;&lt;span class="highlight"&gt;rebound&lt;/span&gt;&amp;nbsp;&lt;span class="highlight"&gt;rates&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;&lt;h4 style="margin: 0px 0.25em 0px 0px; text-transform: uppercase; float: left;"&gt;&lt;span style="font-size: 10pt;"&gt;RESULTS:&lt;/span&gt;&lt;/h4&gt;&lt;p style="margin: 0px 0px 0.5em;"&gt;&lt;span style="font-size: 10pt;"&gt;A total of 12,977&amp;nbsp;&lt;span class="highlight"&gt;patients&lt;/span&gt;&amp;nbsp;from the United Kingdom Collaborative HIV Cohort (UK CHIC) Study achieved a&amp;nbsp;&lt;span class="highlight"&gt;viral&lt;/span&gt;&amp;nbsp;load of less than 50 copies/ml. These&amp;nbsp;&lt;span class="highlight"&gt;patients&lt;/span&gt;&amp;nbsp;contributed a total of 37,314 person-years of follow-up. The overall&amp;nbsp;&lt;span class="highlight"&gt;rebound&lt;/span&gt;&amp;nbsp;rate was 8.07 (7.78, 8.36) per 100 person-years. In adjusted analyses,&amp;nbsp;&lt;span class="highlight"&gt;rates&lt;/span&gt;&amp;nbsp;of&amp;nbsp;&lt;span class="highlight"&gt;viral&lt;/span&gt;&amp;nbsp;&lt;span class="highlight"&gt;rebound&lt;/span&gt;&amp;nbsp;were up to 64%&amp;nbsp;&lt;span class="highlight"&gt;higher&lt;/span&gt;&amp;nbsp;(rate ratio 1.64; 1.43, 1.88) in those who had previously interrupted&amp;nbsp;&lt;span class="highlight"&gt;therapy&lt;/span&gt;&amp;nbsp;compared with those who had not.&amp;nbsp;&lt;span class="highlight"&gt;Patients&lt;/span&gt;&amp;nbsp;who had interrupted at detectable&amp;nbsp;&lt;span class="highlight"&gt;viral&lt;/span&gt;&amp;nbsp;loads had up to a 74% (1.74; 1.42, 2.14)&amp;nbsp;&lt;span class="highlight"&gt;higher&lt;/span&gt;&amp;nbsp;chance of rebounding compared with those who had not interrupted with a detectable&amp;nbsp;&lt;span class="highlight"&gt;viral&lt;/span&gt;&amp;nbsp;load. We found no evidence to suggest interrupting&amp;nbsp;&lt;span class="highlight"&gt;treatment&lt;/span&gt;&amp;nbsp;at an undetectable&amp;nbsp;&lt;span class="highlight"&gt;viral&lt;/span&gt;&amp;nbsp;load was&amp;nbsp;&lt;span class="highlight"&gt;associated&lt;/span&gt;&amp;nbsp;with&amp;nbsp;&lt;span class="highlight"&gt;viral&lt;/span&gt;&amp;nbsp;&lt;span class="highlight"&gt;rebound&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;&lt;h4 style="margin: 0px 0.25em 0px 0px; text-transform: uppercase; float: left;"&gt;&lt;span style="font-size: 10pt;"&gt;CONCLUSION:&lt;/span&gt;&lt;/h4&gt;&lt;p style="margin: 0px 0px 0.5em;"&gt;&lt;span style="font-size: 8pt;"&gt;&lt;span style="font-size: 10pt;"&gt;Among&amp;nbsp;&lt;span class="highlight"&gt;patients&lt;/span&gt;&amp;nbsp;with an undetectable&amp;nbsp;&lt;span class="highlight"&gt;viral&lt;/span&gt;&amp;nbsp;load, having previously interrupted&amp;nbsp;&lt;span class="highlight"&gt;therapy&lt;/span&gt;&amp;nbsp;while the&amp;nbsp;&lt;span class="highlight"&gt;viral&lt;/span&gt;&amp;nbsp;load was detectable is&amp;nbsp;&lt;span class="highlight"&gt;associated&lt;/span&gt;&amp;nbsp;with a raised risk of&amp;nbsp;&lt;span class="highlight"&gt;rebound&lt;/span&gt;.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;

There are no comments on this title.

to post a comment.
London Health Libraries Consortium Privacy notice and Membership terms and conditions